Nykode Therapeutics AS (FRA:5VB)

Germany flag Germany · Delayed Price · Currency is EUR
0.208
+0.011 (5.63%)
Last updated: Dec 5, 2025, 1:25 PM CET
-0.86%
Market Cap 64.35M
Revenue (ttm) 6.26M
Net Income (ttm) -9.38M
Shares Out n/a
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.198
Previous Close 0.197
Day's Range 0.198 - 0.208
52-Week Range 0.086 - 0.288
Beta n/a
RSI 67.51
Earnings Date Nov 24, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2006
Employees 136
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5VB
Full Company Profile

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.